Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Mehr anzeigen
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Adicet made significant progress in 2024 and is well-positioned for success in 2025: Advancing Phase 1 clinical trial evaluating ADI-001 across six autoimmune diseases; preliminary data in lupus...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects to share preliminary Phase 1 clinical data in the first half of 2025 Adicet Bio...
Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0524 | -5.56027164686 | 0.9424 | 0.95 | 0.8738 | 117266 | 0.90413074 | CS |
| 4 | -0.0761 | -7.87703136321 | 0.9661 | 1.11 | 0.8512 | 370413 | 0.96724083 | CS |
| 12 | -0.41 | -31.5384615385 | 1.3 | 1.4 | 0.81 | 627813 | 0.99989981 | CS |
| 26 | -0.72 | -44.7204968944 | 1.61 | 1.6399 | 0.81 | 530745 | 1.21098743 | CS |
| 52 | -2.05 | -69.7278911565 | 2.94 | 3.62 | 0.81 | 895491 | 1.74275506 | CS |
| 156 | -10.85 | -92.4190800681 | 11.74 | 21.87 | 0.81 | 724042 | 5.5594684 | CS |
| 260 | -14.09 | -94.0587449933 | 14.98 | 21.87 | 0.81 | 597234 | 6.85239768 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
